The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Sano Chemicals, Inc. to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis.
The funding will enable Sano Chemicals to complete IND-enabling studies, including establishing an effective formulation, conducting toxicological and stability studies, and filing an IND application for an occidiofungin-based treatment for oral and dermal candidiasis infections. Occidiofungin has demonstrated potent antifungal activity against drug-resistant Candida species, triggers apoptosis in yeast cells, and has shown efficacy in treating systemic and vaginal yeast infections in mice, suggesting its potential as a therapeutic agent for several fungal diseases.
Generated 1/28/25, 11:04 AM